Skip to main content

ARGONAUT: from the synthesis of gAnglioside tumouR antiGens to a platfOrm for caNcer Active immUnoTherapy

Project description

A novel approach for the development of cancer vaccines

Immunotherapy is a promising approach for treating cancer, but so far, cancer vaccines have demonstrated limited success in clinical trials. Recently, the identification of aberrant tumour-associated carbohydrate antigens (TACAs) on the surface of cancer cells has spurred the development of novel cancer vaccines. The EU-funded ARGONAUT project aims to address the problems associated with the development of effective vaccine candidates through novel technologies. The focus will be on vaccines based on ganglioside-type TACAs that are easy to formulate and can elicit an immune response independent of individual genetic variations. The project will offer the possibility for a more tumour-selective immunotherapy approach.


Net EU contribution
€ 207 312,00
Anker Engelunds Vej 101
2800 Kongens Lyngby

See on map

Danmark Hovedstaden Københavns omegn
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00